Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q92915
UPID:
FGF14_HUMAN
Alternative names:
Fibroblast growth factor homologous factor 4
Alternative UPACC:
Q92915; Q86YN7; Q96QX6
Background:
Fibroblast growth factor 14, also known as Fibroblast growth factor homologous factor 4, plays a crucial role in the nervous system's development and function. Its unique position in cellular signaling pathways underscores its importance in maintaining neurological health and stability.
Therapeutic significance:
Spinocerebellar ataxia 27A and 27B, late-onset, are directly linked to mutations in the Fibroblast growth factor 14 gene. These conditions highlight the protein's significant impact on cerebellar function, offering a promising avenue for targeted therapeutic interventions aimed at mitigating these debilitating neurological disorders.